An Exploratory First in Human Phase I Clinical and Pharmacokinetic Study of Intra-tumoral Administration of BO-112 in Adult Patients With Aggressive Solid Tumors, With an Extension Cohort in Combination With Anti-PD1 Treatment
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2017
At a glance
- Drugs BO 112 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Bioncotech Therapeutics
- 12 Dec 2017 Planned number of patients changed from 24 to 36.
- 11 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2019.
- 11 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History